| The calculation of received dose intensity |
| WM Hryniuk and M Goodyear |
|
JCO Dec 1 1990: 1935–1937.
[PDF]
|
 |
| Monoclonal antibodies and radioimmunoconjugates: keeping feasibility at center stage |
| RC Knapp and CC Lau |
|
JCO Dec 1 1990: 1938–1940.
[PDF]
|
|
|
Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer |
| |
JS Stewart, V Hird, D Snook, B Dhokia, G Sivolapenko, G Hooker, JT Papadimitriou, G Rowlinson, M Sullivan, and HE Lambert |
| |
JCO Dec 1 1990: 1941–1950.
[Abstract]
[PDF]
|
|
|
Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE- CytaBOM: a groupwide Southwest Oncology Group study |
| |
TP Miller, S Dahlberg, JK Weick, JC Files, HJ Eyre, KB Pendergrass, and RI Fisher |
| |
JCO Dec 1 1990: 1951–1958.
[Abstract]
[PDF]
|
|
|
Clinical correlates of distinct immunophenotypic and histologic subcategories of lymphocyte-predominance Hodgkin's disease |
| |
A Tefferi, RA Zellers, PM Banks, TM Therneau, and JP Colgan |
| |
JCO Dec 1 1990: 1959–1965.
[Abstract]
[PDF]
|
|
|
Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma |
| |
WD Kaplan, MS Jochelson, TS Herman, LM Nadler, PC Stomper, T Takvorian, JW Andersen, and GP Canellos |
| |
JCO Dec 1 1990: 1966–1970.
[Abstract]
[PDF]
|
|
|
Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group |
| |
CJ Fryer, RJ Hutchinson, M Krailo, RD Collins, LS Constine, DM Hays, RM Heller, PC Davis, J Nachman, and RT O'Brien |
| |
JCO Dec 1 1990: 1971–1980.
[Abstract]
[PDF]
|
|
|
Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group |
| |
CA Sklar, LL Robison, ME Nesbit, HN Sather, AT Meadows, JA Ortega, TH Kim, and GD Hammond |
| |
JCO Dec 1 1990: 1981–1987.
[Abstract]
[PDF]
|
|
|
Pediatric osteosarcoma: therapeutic strategies, results, and prognostic factors derived from a 10-year experience |
| |
M Hudson, MR Jaffe, N Jaffe, A Ayala, AK Raymond, H Carrasco, S Wallace, J Murray, and R Robertson |
| |
JCO Dec 1 1990: 1988–1997.
[Abstract]
[PDF]
|
|
|
Early hospital discharge of children with cancer treated for fever and neutropenia: identification and management of the low-risk patient |
| |
CA Mullen and GR Buchanan |
| |
JCO Dec 1 1990: 1998–2004.
[Abstract]
[PDF]
|
|
|
Current urinary mass screening for catecholamine metabolites at 6 months of age may be detecting only a small portion of high-risk neuroblastomas: a chromosome and N-myc amplification study |
| |
Y Kaneko, N Kanda, N Maseki, K Nakachi, T Takeda, I Okabe, and M Sakurai |
| |
JCO Dec 1 1990: 2005–2013.
[Abstract]
[PDF]
|
|
|
Mechlorethamine, vincristine, and procarbazine chemotherapy for recurrent high-grade glioma in adults: a phase II study |
| |
T Coyle, J Baptista, J Winfield, K Clark, B Poiesz, J Kirshner, A Scalzo, N Newman-Palmer, R King, and S Graziano |
| |
JCO Dec 1 1990: 2014–2018.
[Abstract]
[PDF]
|
|
|
Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effects |
| |
MA Tempero, C Sivinski, Z Steplewski, E Harvey, L Klassen, and HD Kay |
| |
JCO Dec 1 1990: 2019–2026.
[Abstract]
[PDF]
|
|
|
Phase II study of fluorouracil and recombinant interferon alfa-2a in previously untreated advanced colorectal carcinoma |
| |
R Pazdur, JA Ajani, YZ Patt, R Winn, D Jackson, B Shepard, R DuBrow, L Campos, M Quaraishi, and J Faintuch |
| |
JCO Dec 1 1990: 2027–2031.
[Abstract]
[PDF]
|
|
|
Adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with axillary node-positive breast cancer: an update of the Guy's/Manchester trial |
| |
MA Richards, SM O'Reilly, A Howell, WD George, IS Fentiman, MA Chaudary, D Crowther, and RD Rubens |
| |
JCO Dec 1 1990: 2032–2039.
[Abstract]
[PDF]
|
|
|
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry |
| |
SM O'Reilly, RS Camplejohn, DM Barnes, RR Millis, RD Rubens, and MA Richards |
| |
JCO Dec 1 1990: 2040–2046.
[Abstract]
[PDF]
|
|
|
The relative value of conventional staging procedures for developing prognostic models in extensive-stage small-cell lung cancer |
| |
RG Sheehan, EP Balaban, JV Cox, and EP Frenkel |
| |
JCO Dec 1 1990: 2047–2053.
[Abstract]
[PDF]
|
|
|
Phase I clinical and pharmacologic study of intraperitoneal cisplatin and fluorouracil in patients with advanced intraabdominal cancer |
| |
RL Schilsky, KE Choi, J Grayhack, D Grimmer, C Guarnieri, and L Fullem |
| |
JCO Dec 1 1990: 2054–2061.
[Abstract]
[PDF]
|
|
|
Drug-induced DNA damage and tumor chemosensitivity |
| |
RJ Epstein |
| |
JCO Dec 1 1990: 2062–2084.
[Abstract]
[PDF]
|
|
| Further consideration of improved methodology for analyzing local and distant recurrence |
|
|
JCO Dec 1 1990: 2085–2088.
[PDF]
|
|
| Dose reduction of etoposide in jaundiced patients |
| MJ Ratain |
|
JCO Dec 1 1990: 2088–2089.
[PDF]
|
|
| Acute nonlymphocytic leukemia after radiation and MOPP chemotherapy for Hodgkin's disease |
| RS Lavey |
|
JCO Dec 1 1990: 2089–2090.
[PDF]
|
|
| Oligodendroglioma: a new chemosensitive tumor |
| JG Cairncross and DR Macdonald |
|
JCO Dec 1 1990: 2090–2091.
[PDF]
|
|
| Potentiation of cisplatin ototoxicity by noise |
| MA Gratton and BA Kamen |
|
JCO Dec 1 1990: 2091–2092.
[PDF]
|
|
